Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Next-generation gene editing powers new hope for hard-to-treat solid tumors in early human trials.
A pivotal step forward for Duchenne families as gene therapy shows promise to transform neuromuscular care.
While VC investment cools, innovative startups find new ways to fuel biotech innovation and clinical progress.
A historic breakthrough as the first CRISPR-based gene-editing therapy gains FDA approval, offering new hope for sickle cell …
Already a subscriber? Log in